恶性肿瘤引起的肝转移,按其原发部位分为两种。一为腹部消化道癌由门脉转移引起;肝脏是受含癌细胞静脉血侵犯的第一脏器。另外,由全身性血转移引起的肝转移,常合并肺脏和其它脏器的转移。肝脏转移是影响手术预后的一个关键因素。肝转移一般不适宜放射线治疗,手术疗法只限于原发性和局灶性病灶,因此,化疗等全身疗法成为主要对策,但疗效不甚理想。近来,Alfonso等试用静脉注射放射性金胶体治疗微小病灶的肝转移,作为原发病灶切除后预防性治疗措施。并认为在大肠直肠癌手术后,虽然未确诊肝转移,但从原发病灶检查所见,明显怀疑有微小肝转移灶存在,应作为放射性内照射对象。有些学者曾研究含β衰变放射性同位素 Hepatic metastases caused by malignant tumors are divided into two types according to their primary sites. One is that the abdominal gastrointestinal cancer is caused by portal vein metastasis; the liver is the first organ affected by venous blood containing cancer cells. In addition, liver metastases caused by systemic blood metastasis often involve lung and other organ metastases. Liver metastasis is a key factor in the prognosis of surgery. Liver metastases are generally not suitable for radiation therapy. Surgical therapy is limited to primary and focal lesions. Therefore, systemic therapy such as chemotherapy is the main strategy, but the efficacy is not satisfactory. Recently, Alfonso et al.’s trial of intravenous injection of radio-active gold colloids for the treatment of liver metastases from microscopic lesions was used as a preventive measure for primary lesion resection. It is believed that after colorectal cancer surgery, liver metastases have not been diagnosed, but from the observation of primary lesions, microscopic liver metastases are clearly suspected and should be used as internal radioactive targets. Some scholars have studied beta-decay radioactive isotopes